These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23551956)

  • 21. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
    Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ; Jeong H; Chung YA; Park JS; Heo Y; Oh JK; Song IU
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
    Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
    Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
    Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):299-308. PubMed ID: 30689042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
    Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
    Hauser RA; Stocchi F; Rascol O; Huyck SB; Capece R; Ho TW; Sklar P; Lines C; Michelson D; Hewitt D
    JAMA Neurol; 2015 Dec; 72(12):1491-500. PubMed ID: 26523919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China.
    Zhang Z; Shao M; Chen S; Liu C; Peng R; Li Y; Wang J; Zhu S; Qu Q; Zhang X; Chen H; Sun X; Wang Y; Sun S; Zhang B; Li J; Pan X; Zhao G
    Transl Neurodegener; 2018; 7():14. PubMed ID: 29988514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
    Schrempf W; Fauser M; Wienecke M; Brown S; Maaß A; Ossig C; Otto K; Brandt MD; Löhle M; Schwanebeck U; Graehlert X; Reichmann H; Storch A
    Eur J Neurol; 2018 Apr; 25(4):672-679. PubMed ID: 29322594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
    Parkinson Study Group
    Arch Neurol; 2002 Dec; 59(12):1937-43. PubMed ID: 12470183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.